Evaluation of the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration of ICL670 Relative to Deferoxamine(DFO). - Full Text View

Sponsor:	Novartis Pharmaceuticals
Information provided by:	Novartis
ClinicalTrials.gov Identifier:	NCT01090323

Purpose

The safety, tolerability, effects on liver iron concentration and pharmacokinetics of ICL670 is studied in sickle cell disease patients with transfusional hemosiderosis.

Condition	Intervention	Phase
Sickle Cell Disease	Drug: ICL670	Phase 2

Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	A One Year Open Label, Non-comparative Extension to a Randomized, Multicenter, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration (LIC) of Repeated Doses of 5-30mg/kg/Day ICL670 Relative to Deferoxamine (DFO) in Sickle Cell Disease (SCD) Patients With Transfusional Hemosideresis (THS) [Amendment 3: Extension Prolonged to 4-years]

Resource links provided by NLM:

Genetics Home Reference related topics: sickle cell disease

MedlinePlus related topics: Iron Sickle Cell Anemia

Drug Information available for: Deferoxamine mesylate Deferasirox

U.S. FDA Resources

Further study details as provided by Novartis:

Primary Outcome Measures:

Number of Participants With Adverse Events After Start of ICL670 [ Time Frame: 0 - 60 months ] [ Designated as safety issue: Yes ]
Safety as assessed by the number of participants with adverse event or death after the start of ICL670.

Secondary Outcome Measures:

Change in Serum Ferritin From Start of ICL670 to End of Study [ Time Frame: 0 - 60 months ] [ Designated as safety issue: No ]
The main efficacy variable was change in serum ferritin in response to therapy with ICL670. Due to variability of serum ferritin, end of study was considered as the mean of at most the last 3 available observations after the start of ICL670.

Enrollment:	185
Study Start Date:	July 2004
Primary Completion Date:	July 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: ICL670	Drug: ICL670 Daily doses of ICL670 were taken orally 30 minutes before breakfast. The doses range from 5-40 mg/kg and were determined based on the patient's trend in serum ferritin over time during the core study (0109) and on the frequency of blood transfusions the patient received. The treatment duration was up to 4 years.

Detailed Description:

The treatment period started once the patient completed the core study and signed informed consent. It is continued for up to 4 years. Safety parameters were assessed every 4 weeks. Eye and Ear examinations were performed on a yearly basis. To further investigate the extent of iron overload, serum ferritin, iron, and transferrin were monitored every four weeks. The Program Safety Board monitored the safety of ICL670 during the study to evaluate and categorize any serious case reported in association with ICL670.

Eligibility

Ages Eligible for Study:	2 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients were included who met the following criteria:

Completion of the core [Study 0109]
Serum ferritin greater than or equal to 500 µg/L
Ability to comply with all study-related procedures, medications, and evaluations
Sexually active post-menarche female patients must use double-barrier contraception, oral contraceptive plus barrier contraceptive, or must have undergone clinically documented total hysterectomy and/or oophorectomy, tubal ligation or be postmenopausal defined by amenorrhea for at least 12 months.
Written informed consent and assent by the patient and or their parents or legal guardian.

Additional inclusion criteria for pediatric patients The definition of the term 'pediatric' for enrollment and study conduct was in accordance with local law. Parents or the legal guardians were fully informed by the investigator as to the requirements of the study. The pediatric patients themselves were informed according to their capabilities in a language and terms that they were able to understand. Written informed consent was obtained from their legal guardian on the patient's behalf in accordance with national legislation. If capable, all patients had to also personally sign their written informed consent.

Exclusion Criteria:

Patients who met the following criteria were to be excluded:

History of non-compliance to medical regimens and patients who are considered potentially unreliable and/or not cooperative
Serum creatinine above the age-appropriate upper limit of normal within one week prior to entry
Patients with ALT ≥ 500 U/L within one week prior to entry
Evidence of chelation-related cataracts or hearing loss within 4 weeks prior to baseline
Pregnancy (as indicated by serum β-HCG pregnancy test for all female patients with the potential to become pregnant) and patients who are breastfeeding
Patients treated with systemic investigational drug within 4 weeks prior to or with topical investigational drug within 7 days prior to the baseline visit

Other protocol-defined inclusion/exclusion criteria may apply

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01090323

Show 39 Study Locations

Sponsors and Collaborators

Novartis Pharmaceuticals

Investigators

Study Director:

Novartis Pharmaceuticals

More Information

No publications provided

Responsible Party:	External Affairs, Novartis Pharmaceuticals
ClinicalTrials.gov Identifier:	NCT01090323 History of Changes
Obsolete Identifiers:	NCT00171197
Other Study ID Numbers:	CICL670A0109E1, EudraCT no. 2004-000597-31
Study First Received:	March 15, 2010
Results First Received:	December 21, 2010
Last Updated:	May 3, 2011
Health Authority:	United States: Food and Drug Administration Italy: Ministry of Health Canada: Health Canada France: Comité consultatif sur le traitement de l'information en matière de recherche dans le domaine de la santé United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Novartis:

Deferasirox
ICL670A
Iron chelators
Sickle Cell Disease
Transfusional Hemosiderosis

Additional relevant MeSH terms:

Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hematologic Diseases
Hemoglobinopathies
Genetic Diseases, Inborn

Deferoxamine
Deferasirox
Siderophores
Iron Chelating Agents
Chelating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 23, 2012